Skip to main content

Table 2 (A) HCC Incidence and hazard ratios in studies evaluating people with HBV and (B) HCC incidence and hazard ratios in studies evaluating people with HCV

From: Can statins lessen the burden of virus mediated cancers?

All

Statin users

Statin non-users

Study

Follow up period

No. HCC cases

HCC incidence (%)

HCC incidence rate (per 100,000 py)

Model adjustment(s)

No. HCC cases

HCC incidence (%)

HCC incidence rate (per 100,000 py)

(a) HR and 95% CI

No. HCC cases

HCC incidence (%)

HCC incidence rate (per 100,000 py)

HR and 95% CI

All

1st cDDD group

2nd cDDD group

3rd cDDD group

4th cDDD group

LS group

HS group

(A)

Goh [52]

7.2 years

702

9.1

N/A

Age, sex, cirrhosis, DM, HTN, HBV DNA level, ALT level, total cholesterol, antiviral/anti-platelet medications

30

3.3

N/A

0.36, 0.19–0.68

0.63, 0.31–1.29 [28–365 cDDD]

0.51, 0.21–1.25 [366–730 cDDD]

0.32, 0.07–1.36 [731–1095 cDDD]

0.17, 0.06–0.48 [> 1095 cDDD]

0.35, 0.16–0.78

0.39, 0.15–1.05

672

7.9

N/A

Ref

Hsiang [54]

393,154 py

1298

2.43c

520

Propensity score

36

3.1c

1240

0.68, 0.48–0.97

      

1262

2.4c

510

Ref

Simon [56]*

8 years

136c

3.5c

289c

Propensity score

54c

2.8c

209c

N/A

    

0.58, 0.48–0.78

0.94, 0.84–1.14

82c

4.2c

386c

Ref

Tsan [50]

328,946 py

1021

3.1c

310

Age, sex, income, urbanization, diabetes, cirrhosis

58c

2.1c

211

0.47, 0.36–0.61

0.66, 0.44–0.99 [28–90 cDDD]

0.41, 0.27–0.61 [91–365 cDDD]

0.34, 0.18–0.67 [> 365 cDDD]

 

0.44, 0.33–0.59

0.51, 0.31–0.85

963

3.1c

320

Ref

Yang [58]**

5782 py

23

1.7

398

Age sex, tobacco, alcohol, BMI, cirrhosis

1

2.9

N/A

13.64, 0.84–221.23

      

13

8.9

N/A

57.22, 6.95–470.96

(B)

Simon [55]

97.9 mos (statin users); 81.6 mos (nonusers)

239

2.6

N/A

Baseline FIB-4

73

1.8

300 (28–89 cDDD), 200 (90–180 cDDD), 215 (> 180 cDDD)

0.53, 0.36–0.72

0.85, 0.47–1.53 [28–89 cDDD]

0.48, 0.27–0.88 [90–180 cDDD]

0.51, 0.36–0.72 [> 180 cDDD]

   

160

3.2

465

Ref

Simon [56]*

8 years

480

3.8c

296c

Propensity score

211

3.3c

232c

N/A

    

0.54, 0.45–0.83

0.96, 0.87–1.10

269

4.2c

377c

Ref

Tsan [57]

2,792,017 py

27,883

10.7

999

Age, sex, urbanization, income, cirrhosis, DM

1378

3.9c

341

0.53, 0.49–0.58

0.66, 0.59–0.74 [28–89 cDDD]

0.47, 0.40–0.56 [90–180 cDDD]

0.33, 0.25–0.42 [> 180 cDDD]

   

26,505

11.7c

1110

Ref

  1. (a) HR hazard ratio (adjusted HR reported if available), cDDD cumulative defined daily statin doses, DM diabetes, FIB-4 fibrosis-4 score, HBV hepatitis B virus, HCC hepatocellular carcinoma, HTN hypertension, HS hydrophilic statin users, LS lipophilic statin users, py person years, Ref reference
  2. *Note that this publication is included in both tables (its HBV data in Table 2A and it's HCV data in Table 2B)
  3. **This cohort includes only persons with diabetes
  4. cValue calculated from available study data
Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us